Host-directed strategies using lipid nanoparticles to reduce mycobacteria survival

Insights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticles

“…Superior tolerability (owing to their genesis in physiological lipids), scaling up practicality, the capacity to integrate hydrophobic or hydrophilic drugs and enhanced drug stability are the main defining features of SLNPs ( Kaur and Singh, 2014 ). Pereira and colleagues developed a host-directed strategy against Mtb infection by designing a biocompatible nanocarrier for phage-derived protein delivery, using M. smegmatis as a model ( Pereira et al, 2015 ). The rationale behind the study design was that Mtb pathogenicity is strongly supported by the presence of lipids in the cell wall.…”

“…The rationale behind the study design was that Mtb pathogenicity is strongly supported by the presence of lipids in the cell wall. Thus, its degradation induces bacterial destruction through cell wall hydrolysis ( Pereira et al, 2015 ). The proposed Ms6 LysB-containing lipid nanocarrier (SLN LysB) investigated the known benefits of nano-based systems for selectively targeting phagocytic cells, allowing LysB intracellular accumulation and more effective Mtb infection eradication ( Pereira et al, 2015 ).…”

“…Thus, its degradation induces bacterial destruction through cell wall hydrolysis ( Pereira et al, 2015 ). The proposed Ms6 LysB-containing lipid nanocarrier (SLN LysB) investigated the known benefits of nano-based systems for selectively targeting phagocytic cells, allowing LysB intracellular accumulation and more effective Mtb infection eradication ( Pereira et al, 2015 ). The adsorption efficiency value suggested the system's potential as a protein nanocarrier.…”

Nanotechnology Based Therapeutics, Drug Delivery Mechanisms and Vaccination approaches for Countering Mycobacterium avium subspecies paratuberculosis (MAP) Associated Diseases

“…Recently, a lipid nanocarrier containing phage lipolytic enzyme has been designed as drug delivery system for treating mycobacterial infection (Pereira et al, 2015). Pereira et al (2015) loaded LysB enzyme (a phage mycolylarabinogalactan esterase that break the lipids in cell wall of mycobacteria) on lipid nanocarrier.…”

“…Pereira et al (2015) loaded LysB enzyme (a phage mycolylarabinogalactan esterase that break the lipids in cell wall of mycobacteria) on lipid nanocarrier. This system selectively targets the phagocytic cells facilitating intracellular accumulation of LysB causing mycobacterial suppression.…”